Capstone Investment Advisors
TVTX icon

Capstone Investment Advisors’s Travere Therapeutics TVTX Stock Holding History

Capstone Investment Advisors’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-514,700
Closed -$4.63M – 2552
2023
Q4 		$4.63M Hold
514,700
– – 0.01% 548
2023
Q3 		$4.6M Buy
514,700
+214,700
+72% +$3.03M 0.02% 449
2023
Q2 		$4.61M Buy
+300,000
New +$5.46M 0.02% 397

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Capstone Investment Advisors's TVTX Position: Q4 2025 in Review

Capstone Investment Advisors sold out of Travere Therapeutics (TVTX) in Q4 2025, closing a stake of 13,440 shares — an estimated $321K sold.

Capstone Investment Advisors first reported a position in TVTX in Q4 2023 and held it in 3 quarters. The position peaked at $321K in Q3 2025. 278 funds tracked by Wall St. Rank hold TVTX as of Q4 2025.

  • Capstone Investment Advisors reported no remaining Travere Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Capstone Investment Advisors sold 13,440 Travere Therapeutics shares in Q4 2025, an estimated $321K.
  • Capstone Investment Advisors first reported a position in Travere Therapeutics in Q4 2023 and held it in 3 quarters.
  • Capstone Investment Advisors's Travere Therapeutics position peaked at $321K in Q3 2025.
  • 278 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2025.

Based on Capstone Investment Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.